GW/TMH:gte 02/17/05 PATENT Attorney Reference Number 6395-64908-01



EXPRESS MAIL LABEL NO. EV514608418US DATE OF DEPOSIT: February 17, 2005 Application Number 09/826,115

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6395-64908-01
Application Number	09/826,115
Filing Date	April 4, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
AROSTANCE		WIPO/PCT	WO 92/02548 (French w/English translation)	20 Feb. 1992	Institut Pasteur
8		WIPO/PCT	WO 02/072036	29 Sept. 2002	Yale University & L2 Diagnostics, LLC
. \		WIPO/PCT	WO 02/083903	24 Oct 2002	Brown University Research Foundation
→ -	\neg	Japan	JP 89025725 (English Abstract only)	May 1989	ZH Biseibutsu Kagaku Ken
		Japan	JP 53133627 (English Abstract only)	Nov 1978	Nippon Seibutsu KK
	ASSIR		JP 63004895 (English Abstract only)	1963	Saikin Seizai Yoka
	alt	Japan	JP 63105682 (English Abstract only)	23 Oct 1986	Mitsubishi Kasei Corp
		Japan	JP 65000611 (English Abstract only)	1965	Nippon Seibutsu KK
		Japan	JP 67025408 (English Abstract only)	1967	Okuj
+ -	1	Japan	JP 7265093 (English Abstract only)	Oct 1995	Tokyo To Shinkei Kagaku Sogo Kenkyusho
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
8		ABERLE et al., "A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms," J. Immunol. 163:6756-6761, 1999			
•		FONSECA et al., "Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice," Vaccine 12:279-285, 1994			

EXAMINER SIGNATURE:	DATE CONSIDERED: 05/11/05
* Everyinary Initial if a forence and developed and a leafure and in	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

GW/TMH:gte 02/17/05 PATENT Attorney Reference Number 6395-64908-01



EXPRESS MAIL LABEL NO. EV514608418US DATE OF DEPOSIT: February 17, 2005 Application Number 09/826,115

	PAOSibistic Co.	Attorney Docket Number	6395-64908-01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/826,115	
		Filing Date	April 4, 2001	
		First Named Inventor	Chang	
		Art Unit	1648	
		Examiner Name	Jeffrey S. Parkin	
8	JACOBS et al., "High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model," J. Virol. 66:2086-2095, 1992 JACOBS, "A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge," Clinical Science 85:117-122, 1993 MASON et al., "Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1," Virology 161:262-267, 1987			
	MONATH, "Flaviviruses," Virology	(R.N. Fields, ed.) 763-814,	1990	
,	PINCUS et al., "Recombinant vacci fever virus protects mice from lethal 1992	PINCUS et al., "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," Virology 187:290-297, 1992		
	RAMELOW et al., "Detection of tick-borne encephalitis virus RNA in ticks (Ixodes ricinus) by the polymerase chain reaction," J. Virological Methods 45:115-119, 1993			
	SCHALICH et al., "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," J. Virol. 70(7):4549-4557, 1996			
	SMITHBURN et al., "A neurotropio	SMITHBURN et al., "A neurotropic virus isolated from the blood of a native of uganda," Am. J. Trop. Med. 20: 471-492, 1940		
.4				

EXAMINER SIGNATURE:		DATE CONSIDERED:
* F	C	and with MPED 600. Draw line through site if not

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.